More recently, the CREDENCE trial assessed the effects of canagliflozin, an SGLT2 inhibitor, on renal composite outcomes as a primary endpoint, and those results showed kidney-protective effects in patients with T2D and chronic kidney disease (CKD) (5). The gene discussed is SLC5A2; the disease is chronic kidney disease.